The life cycle of metabolism
March 23, 2026 / Metabolism Across Lifespan / Epigenetics and Metabolic Health / Obesity and Diabetes Risk Factors / Early Life Metabolic Programming / Lifestyle and Metabolic Disease Prevention
Metabolism evolves across the lifespan, influenced by genetics, epigenetics, lifestyle, and environment, beginning before birth and shaping lifelong risk for obesity, diabetes, and metabolic disease, underscoring the importance of early intervention and sustained healthy behaviors.
Pythons’ feast-and-famine life hints at new weight-loss pathway
March 19, 2026 / Novel Obesity Metabolic Pathways / Gut Derived Appetite Regulation / pTOS Metabolite Weight Loss / Hypothalamic Feeding Regulation / Next Generation Obesity Therapeutics
Researchers identified a python-derived metabolite (pTOS) that suppresses appetite and induces weight loss in obese mice by targeting hypothalamic pathways, revealing a novel gut-derived metabolic signaling mechanism with potential for future obesity therapeutics.
Kalohexis emerges from stealth to advance obesity and metabolic diseases treatments
March 19, 2026 / Obesity Drug Development Pipeline / Metabolic Disease Therapeutics / Biotech Startup Obesity Treatment / Cardiometabolic Drug Innovation / Next Generation Obesity Therapies
Kalohexis launched as a new biotechnology company focused on developing therapies for obesity and metabolic diseases, reflecting continued industry expansion and investment in innovative approaches to address chronic cardiometabolic conditions.
Current status survey and risk factor analysis of metabolic dysfunction-associated steatotic liver disease among adolescents in Hainan Province
March 22, 2026 / Adolescent MASLD Risk Factors / Pediatric Fatty Liver Disease / Obesity and Liver Disease Risk / Dietary Impact on MASLD / Metabolic Liver Disease Prevention
A study in Chinese adolescents found a 7.64% prevalence of MASLD, with obesity, family history, and unhealthy dietary habits as key risk factors, while regular fruit and vegetable intake showed protective effects against metabolic liver disease.
Children with obesity are at risk of illness despite normal test results, study shows
March 23, 2026 / Childhood Obesity Long Term Risk / Metabolically Healthy Obesity Children / Pediatric Type 2 Diabetes Risk / Early Obesity Intervention Benefits / Cardiometabolic Disease Prevention
Children with obesity, even without metabolic abnormalities, face increased long-term risks of type 2 diabetes, hypertension, and dyslipidemia, with early obesity treatment significantly reducing future cardiometabolic disease risk.
Molecule in python blood could pave way for new obesity drugs, scientists say
March 19, 2026 / pTOS Metabolite Weight Loss / Appetite Regulation Hypothalamus / Novel Obesity Drug Mechanisms / Gut Microbiome Metabolites / GLP1 Alternative Therapies
Researchers identified a python-derived metabolite, pTOS, that suppresses appetite and induces weight loss in obese mice by acting on hypothalamic pathways, representing a novel mechanism distinct from GLP-1 therapies and a potential target for future obesity drugs.
GLP-1 Therapies May Benefit Both Metabolic and Mental Health
March 23, 2026 / GLP1 Mental Health Benefits / Semaglutide Depression Anxiety Reduction / Obesity Diabetes Psychiatric Outcomes / GLP1 Neurobiological Effects / Metabolic and Mental Health Therapy
GLP-1 therapies, particularly semaglutide, are associated with reduced risks of depression, anxiety, substance use, and psychiatric hospitalizations, suggesting potential dual benefits on metabolic and mental health, possibly through both indirect and neurobiological mechanisms.
Patients who stop GLP-1 drugs often restart or try alternatives
March 17, 2026 / GLP1 Therapy Discontinuation / Obesity Treatment Switching Patterns / Semaglutide Tirzepatide Outcomes / Weight Loss Maintenance Strategies / Chronic Obesity Management
Many patients discontinuing GLP-1 therapies restart treatment or switch to alternative obesity interventions, with varied weight outcomes, highlighting the need for sustained, individualized management strategies to maintain long-term cardiometabolic benefits.
Activating hypoxia signaling improves metabolism and bone health
March 17, 2026 / Hypoxia Inducible Factor Metabolism / Obesity Bone Health Connection / Metabolic Disease Bone Loss / HIF Signaling Therapeutics / Glucose Metabolism and Bone Integrity
Activation of hypoxia-inducible factor signaling improved metabolic function and bone health in obesity models by reducing fat accumulation, enhancing glucose control, and preserving bone vascular integrity, suggesting a dual therapeutic strategy for metabolic and skeletal complications.
Early morning workouts may improve cardiometabolic health
March 19, 2026 / Morning Exercise Benefits / Cardiometabolic Disease Prevention / Exercise Timing Health Outcomes / Cardiovascular Risk Reduction / Type 2 Diabetes Obesity Link
Early morning exercise is associated with reduced risk of cardiometabolic diseases, including coronary artery disease, hypertension, diabetes, and obesity, independent of activity level, highlighting exercise timing as a potential factor in preventive cardiovascular and metabolic health strategies.
HK2 protein identified as potential treatment target for MASH: Study
March 23, 2026 / MASH Treatment Target / HK2 Protein Liver Disease / S100A11 Metabolic Pathway / Steatotic Liver Disease Research / Liver Fibrosis Therapeutics
HK2 and S100A11 proteins drive liver fat accumulation and inflammation in MASH. Targeting S100A11 reduces HK2 levels, improving steatosis and fibrosis in preclinical models, positioning HK2 as a promising therapeutic target for metabolic liver disease.
Expert consensus validates UDFF for noninvasive fatty liver assessment
MARch 17, 2026 / UDFF Fatty Liver Imaging / Noninvasive Liver Diagnosis / MASLD Assessment Tool / Hepatic Steatosis Quantification / Liver Imaging Innovation
Expert consensus supports UDFF as a reliable, noninvasive method for quantifying hepatic steatosis, demonstrating high diagnostic accuracy and reproducibility, offering a scalable alternative to biopsy and MRI for MASLD screening and monitoring across diverse patient populations.
Identifying genetic contributions of 6q21 loci and PPAR pathway to antipsychotic-induced metabolic syndrome: a Sex-Stratified Multi-Omics study
March 21, 2026 / Antipsychotic Metabolic Syndrome / PPAR Signaling Pathway / 6q21 Genetic Variants / Multiomics Risk Prediction / Personalized Psychiatry Medicine
A multi-omics study identifies 6q21 genetic variants and PPAR signaling as key drivers of antipsychotic-induced metabolic syndrome, particularly in males, enabling improved risk prediction and highlighting targets for personalized prevention of cardiometabolic complications.
Korea University study identifies liver–metabolic disease as a key risk factor for heart failure in older adults with atrial fibrillation
March 23, 2026 / Atrial Fibrillation Heart Failure / Steatotic Liver Disease Risk / MASLD MetALD ALD / Liver Heart Axis / Cardiometabolic Disease Integration
Steatotic liver disease significantly elevates heart failure risk in older atrial fibrillation patients, with risk increasing across MASLD, MetALD, and ALD, underscoring the liver–heart axis and need for integrated cardiometabolic risk assessment and early intervention.
New Metabolic Health Ingredient Targets Abdominal Fat, as Demand Grows for Evidence-Based Solutions
March 18, 2025 / Metabolic Health Ingredients / Abdominal Fat Reduction / Adipose Inflammation Pathways / Mitochondrial Energy Metabolism / Cardiometabolic Disease Prevention
Re-Vaya, a novel metabolic health ingredient, targets abdominal fat by modulating inflammation and enhancing mitochondrial energy metabolism, reflecting a shift toward evidence-based approaches addressing underlying metabolic dysfunction linked to obesity and cardiometabolic disease risk.
A healthier thymus predicts longer life and lower cancer and heart disease risk in adults
March 19, 2026 / Thymus Immune Aging / Cancer Cardiovascular Risk / AI Imaging Biomarkers / T Cell Function Longevity / Immune System Health
Higher thymic health, assessed via AI-based imaging, is associated with reduced mortality, cancer, and cardiovascular risk, highlighting the thymus as a key regulator of immune aging and a potential biomarker for long-term health outcomes.
Snow Medical backs Australia’s national effort to tackle deadly liver disease with $15.5 M funding
March 21, 2026 / Fatty Liver Disease Research / MAFLD Public Health / Liver Disease Funding Initiative / Metabolic Syndrome Liver Risk / Liver Disease Innovation
A $15.5M Australian initiative will advance research in metabolic-associated fatty liver disease, aiming to improve diagnosis, treatment, and prevention amid rising global burden linked to obesity and diabetes, positioning MAFLD as a critical public health priority.
Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes
March 19, 2026 / GLP1 Type 1 Diabetes / Cardiovascular Kidney Outcomes / Cardiorenal Risk Reduction / Diabetes Therapeutics / GLP1 Safety Efficacy
GLP-1 receptor agonists in type 1 diabetes are associated with reduced cardiovascular events and end-stage kidney disease without increased hypoglycemia or ketoacidosis risk, supporting their potential role in improving long-term cardiorenal outcomes.
Data-driven subgroups for 3-year risk stratification of incident diabetes and complications in diabetes-free Chinese adults
March 20, 2025 / Diabetes Risk Stratification / Metabolic Subgroups AI / Precision Prevention Diabetes / Cardiometabolic Risk Prediction / Polygenic Risk Integration
Machine learning identified distinct metabolic subgroups in diabetes-free adults, improving 3-year prediction of diabetes, cardiovascular disease, and fatty liver risk, supporting precision prevention strategies that integrate clinical and genetic data for early intervention.